Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg | Getty Images Danish pharmaceutical giant Novo Nordisk on Wednesday announced plans to cut around 9,000 roles, or roughly 11.5% of its global workforce. “Novo Nordisk today announced a company-wide transformation to simplify its organisation, improve the speed of decision-making, and reallocate resources …
Read More »Novo Nordisk Says Wegovy Cuts Heart Risk by 57% Compared With Eli Lilly’s Obesity Drug – WSJ The Wall Street Journal Novo Nordisk’s Wegovy cuts heart risk by 57% versus rival Lilly weight-loss drug in study Reuters Wegovy trial result gives boost to Novo Nordisk amid U.S. market woes CNBC Novo’s Wegovy Beats Lilly’s Zepbound for Heart Health, Study Finds. What It Means …
Read More »
Novo Nordisk (NVO) stock was down on Tuesday, despite a lack of news from the pharmaceutical company. Instead, investors can turn to rival drug maker Eli Lilly (LLY) to learn why shares of NVO stock have fallen today. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights …
Read More »Drugmaker Novo Nordisk freezes hiring for non-critical jobs Reuters Novo Nordisk’s new CEO is said to start hiring freeze to cut costs (NVO:NYSE) Seeking Alpha Novo Nordisk’s New CEO Starts Hiring Freeze in Cost-Cutting Push Bloomberg.com Pharmalittle: We’re reading about a Novo hiring freeze, coverage for GLP-1 drugs, and much more statnews.com Novo Nordisk’s Human Capital Shift: A Calculated Bet on R&D Efficiency and …
Read More »
GoodRx Announces Collaboration with Novo Nordisk to Expand Access to Ozempic Business Wire Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patients CNBC GoodRx stock soars after striking deal to sell Novo Nordisk’s GLP-1s for $499/month Yahoo Finance Novo Nordisk halves US price of Ozempic Financial Times Novo Nordisk offers Ozempic at $499 per month to eligible …
Read More »Novo Nordisk offers Ozempic at $499 per month to eligible US cash-paying customers Reuters Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patients CNBC GoodRx stock soars after striking deal to sell Novo Nordisk’s GLP-1s for $499/month Yahoo Finance Novo Nordisk halves US price of Ozempic Financial Times Novo Halves Ozempic Price to $499 a Month for …
Read More »Dayforce, Novo Nordisk, GoodRx, UnitedHealth, Sunrun, TeraWulf, and More Movers Barron’s Stocks making the biggest moves premarket: Dayforce, Sunrun, Tesla, Novo Nordisk and more CNBC 5 Things to Know Before the Stock Market Opens Investopedia Stocks to Watch Monday: Novo Nordisk, TeraWulf, UnitedHealth, Soho House The Wall Street Journal Top Stock Movers Now: Dayforce, Novo Nordisk, First Solar, and More Yahoo Finance Source link
Read More »Wegovy News Pushes Novo Nordisk Stock Higher Barron’s Novo Nordisk shares pop after Wegovy receives U.S. approval for liver disease CNBC Wegovy Gets F.D.A. Approval for MASH The New York Times Novo’s Wegovy becomes first GLP-1 drug approved for MASH BioPharma Dive FDA Approves Novo Nordisk’s Wegovy for Liver Disease The Wall Street Journal Source link
Read More »Novo Nordisk partners with GoodRx for $499 monthly Ozempic, Wegovy (GDRX:NASDAQ) Seeking Alpha GoodRx stock soars after striking deal to sell Novo Nordisk’s GLP-1s for $499/month Yahoo Finance Novo Nordisk halves US price of Ozempic Financial Times Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patients CNBC Novo Halves Ozempic Price to $499 a Month for Those …
Read More »
(Reuters) -Novo Nordisk said on Monday that it was launching a new offer for self-paying type 2 diabetes patients in the U.S. to access Ozempic for $499 per month. The company said this was part of its ongoing efforts to explore new collaborations and approaches towards improving access to authentic semaglutide medicines. It said the offer would be available through …
Read More »